|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.38 USD | +0.84% |
|
+1.57% | +8.99% |
| 05-22 | BioSyent Inc., Q1 2026 Earnings Call, May 14, 2026 | |
| 05-19 | BioSyent Secures Health Canada Nod For Hypothyroidism Oral Solution | MT |
| Market Cap | 167M 119M 104M 95.99M 88.68M 11.41B 170M 1.14B 449M 5.59B 446M 436M 19.24B | P/E 2026 * |
16.4x | P/E 2027 * | 13.5x |
|---|---|---|---|---|---|
| Enterprise Value | 167M 119M 104M 95.99M 88.68M 11.41B 170M 1.14B 449M 5.59B 446M 436M 19.24B | EV / Sales 2026 * |
2.42x | EV / Sales 2027 * | 2.03x |
| Free-Float |
64.14% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioSyent Inc.
| 1 day | +0.84% | ||
| 1 week | +1.57% | ||
| Current month | +1.63% | ||
| 1 month | +3.76% | ||
| 3 months | -4.54% | ||
| 6 months | +11.33% | ||
| Current year | +8.99% |
| 1 week | 10.28 |  | 10.38 |
| 1 month | 9.76 | | 10.38 |
| Current year | 9 | | 12 |
| 1 year | 7.63 | | 12 |
| 3 years | 5.54 | | 12 |
| 5 years | 4.69 | | 12 |
| 10 years | 2.15 | | 12 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 66 | 1999-04-30 |
Robert March
DFI | Director of Finance/CFO | - | 2018-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 2015-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Sara Elford
BRD | Director/Board Member | 55 | 2018-01-07 |
Prakash Gowd
BRD | Director/Board Member | 62 | 2025-05-14 |
René Goehrum
CHM | Chairman | 66 | 1999-05-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.84% | +1.57% | - | - | 118M | |
| -2.48% | -6.72% | +44.19% | +156.43% | 1,054B | |
| -1.52% | -5.01% | +61.87% | +58.79% | 621B | |
| -1.30% | -3.88% | +27.81% | +79.97% | 438B | |
| -1.12% | -3.68% | +26.89% | +20.58% | 325B | |
| -1.73% | -3.45% | +26.95% | +44.09% | 281B | |
| -1.95% | -13.92% | +15.96% | +19.76% | 262B | |
| -1.45% | -2.37% | -27.87% | -39.87% | 219B | |
| -1.44% | -3.49% | +19.60% | +56.20% | 195B | |
| -1.04% | -4.63% | +16.01% | +68.47% | 163B | |
| Average | -1.03% | -4.15% | +23.49% | +51.60% | 395.13B | |
| Weighted average by Cap. | -0.90% | -4.77% | +33.17% | +77.04% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 69M 49.09M 42.9M 39.66M 36.64M 4.72B 70.25M 473M 186M 2.31B 184M 180M 7.95B | 82.3M 58.55M 51.17M 47.3M 43.7M 5.62B 83.79M 564M 221M 2.75B 220M 215M 9.48B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-14 | US$10.38 | +0.84% | 2,697 |
| 26-07-13 | US$10.29 | +0.10% | 1,762 |
| 26-07-10 | US$10.28 | -0.62% | 1,600 |
| 26-07-08 | US$10.34 | +1.25% | 120 |
| 26-07-07 | US$10.22 | -0.91% | 1,302 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
14.60CAD
Average target price
18.00CAD
Spread / Average Target
+23.29%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RX Stock
- BIOYF Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
